Enhertu (Trastuzumab Deruxtecan) and Pertuzumab (Perjeta) Treatment Regimen
In this article
A New Standard: Enhertu + Pertuzumab
Enhertu (Trastuzumab Deruxtecan) + Pertuzumabis a next-generation regimen for first-line treatment of metastatic or unresectable HER2-positive breast cancer , replacing conventional chemotherapy combinations (taxane + trastuzumab + pertuzumab), with FDA approval in December 2025.
The combination aims to reduce conventional chemotherapy's systemic side effects while using tumor-specific “smart bomb” (ADC) technology and “dual HER2 blockade” to take progression-free survival (PFS) to unprecedented levels.
- Indication: Metastatic HER2(+) Breast Cancer – 1st Line.
- Mechanism: Antibody–Drug Conjugate (ADC) + Dimerization Inhibitor.
- Evidence: DESTINY-Breast09 Trial (PFS Advantage).
- Interstitial Lung Disease (ILD): The most critical risk.
- Cardiotoxicity: Reduced LVEF.
- Gastrointestinal: Nausea, vomiting (high emetic risk).
- Hematologic: Neutropenia, anemia.
- Extend PFS (time without progression) beyond 40 months.
- Avoid conventional taxane chemotherapy toxicity.
- Potential intracranial activity (brain metastases).
Key Indications and Patient Selection
HER2-Positive Metastatic Breast Cancer (1st Line)
For patients with tumor tissue confirmed as IHC 3+ or ISH (+) HER2-positive, with no prior systemic treatment in the metastatic setting (or >6 months after adjuvant treatment), this is a new standard of care option.
Comparison With Conventional THP
Suitable and Higher-Risk Patient Profiles
- ECOG performance status 0-1.
- Healthy lung parenchyma (no COPD or fibrosis history).
- Normal cardiac function (LVEF above 50%).
- History of ILD: Prior drug-induced or radiation pneumonitis (Enhertu may be contraindicated).
- Cardiac Risk: History of heart failure.
- Renal/Hepatic Impairment: May require dose adjustment or close monitoring.
Enhertu (Trastuzumab Deruxtecan - T-DXd)
Enhertu is an Antibody–Drug Conjugate (ADC). A potent chemotherapy agent (topoisomerase I inhibitor) is attached to a HER2-binding antibody, trastuzumab.
- Trojan Horse Effect: The drug enters the cell and releases its payload inside.
- Bystander Effect: The drug can cross the cell membrane and kill neighboring HER2-negative cancer cells, critical in heterogeneous tumors.
Pertuzumab (Perjeta)
A monoclonal antibody preventing HER2 dimerization (pairing). It blocks HER2 from combining with HER3 to send powerful growth signals. Together with Enhertu, it provides complete two-pronged receptor blockade .
The phase 3 trial underpinning approval was DESTINY-Breast09. In this global study of more than 1100 patients:
- PFS (Progression-Free Survival): Median PFS with Enhertu + Pertuzumab was 40.7 months , versus 26.9 months with standard THP.
- Objective Response Rate (ORR): Tumor shrinkage rates were higher in the Enhertu arm.
- Intracranial Effect: Systemic control was also demonstrated in patients with stable brain metastases.
Treatment is generally given every 3 weeks (21-day cycles) .
Regimen Details
- 1. Enhertu (T-DXd):
- Dose: 5.4 mg/kg IV infusion.
- Duration: First dose over 90 minutes; subsequent doses over 30 minutes if well tolerated.
- Diluent: 5% Dextrose Only (Do not use normal saline).
- 2. Pertuzumab:
- Loading Dose (Cycle 1): 840 mg IV (60 minutes).
- Maintenance Dose (Cycle 2 onward): 420 mg IV (30-60 minutes).
- May be given after Enhertu.
- Enhertu has high/moderate emetic risk. Give a two- or three-drug antiemetic regimen (5-HT3 antagonist + Dexamethasone ± NK1 inhibitor).
- Premedication may be needed to prevent infusion reactions.
A. Interstitial Lung Disease (ILD) / Pneumonitis
- Symptoms: Cough, shortness of breath, fever, new radiological opacities.
- Management: Stop the drug as soon as suspected. For symptomatic cases (Grade 2+), permanently discontinue and start high-dose steroids.
B. Cardiotoxicity
Both drugs, particularly in combination, may affect cardiac muscle function (LVEF). During treatment, echocardiography/MUGA every 3 months is mandatory.
C. Other Common Side Effects
- Nausea and Vomiting: Effective antiemetic treatment is essential.
- Alopecia (Hair Loss): Although taxane-free, Enhertu may cause hair loss in 40-50%.
- Neutropenia: Reduced immune cells, increasing infection risk.
- Diarrhea: Usually mild to moderate (Pertuzumab-related).
Pertuzumab doses are not reduced: it is either given or stopped. Enhertu may be reduced according to toxicity.
| Toxicity / Situation | Management Strategy |
|---|---|
| ILD (Asymptomatic – Grade 1) | Withhold. Consider steroids. Restart after recovery. |
| ILD (Symptomatic – Grade 2+) | Enhertu PERMANENTLY DISCONTINUE. Start systemic steroids. |
| Neutropenia (Grade 3-4) | Delay treatment. After recovery, resume one dose level lower (5.4 -> 4.4 mg/kg). |
| LVEF Decline (40-45%) | Delay treatment. Reassess after 3 weeks. Permanently discontinue if not improved. |
This treatment combines two targeted drugs binding to the “antennas” (HER2) on breast cancer cells. Pertuzumab stops the antennas from signaling, while Enhertu binds and releases a potent drug inside the cell.
Treatment is given by IV infusion every 3 weeks . It may not cause complete hair loss like conventional chemotherapy, although thinning can occur, and generally causes less fatigue. However, if you develop a dry cough or shortness of breath , notify your doctor immediately, as this may indicate lung sensitivity.
- Pertuzumab: Authorized in Türkiye. SGK covers its conventional THP combination, but the new Enhertu combination is not yet reimbursed.
- Enhertu: Authorized by TİTCK. For 1st-line use, off-label approval or additional applications may generally be needed. Not reimbursed by SGK.
- For the current situation, patients may pursue legal action after the off-label application process.
- FDA Approval Announcement, December 15, 2025. Fam-trastuzumab deruxtecan-nxki in combination with pertuzumab.
- DESTINY-Breast09 Trial Results. Trastuzumab Deruxtecan with or without Pertuzumab versus THP in First-line HER2+ Metastatic Breast Cancer.
- Enhertu (fam-trastuzumab deruxtecan-nxki) Prescribing Information. Daiichi Sankyo / AstraZeneca.
- Perjeta (pertuzumab) Prescribing Information. Genentech/Roche.
- ESMO Guidelines for Metastatic Breast Cancer (Updated 2025).
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.